Sales of Anemia Drugs May Be Hurt by New Recommendations

The National Kidney Foundation said Thursday it plans to cut its recommended target for hemoglobin levels in kidney disease patients -- a move that could hurt sales of lucrative anemia drugs that boost hemoglobin but have come under scrutiny over safety concerns.

The changes could hurt sales of Amgen key anemia drugs Aranesp and Epogen, which brought in $6.6 billion in 2006, and Johnson & Johnson's

Procrit, which saw $3.2 billion in sales, although some analysts say that drug has become a less-critical product for the company.